Innovative, long-acting treatments – for patients and society
Camurus is committed to improving the lives of patients with severe and chronic diseases
Learn more
Disease areas
Focus on severe and chronic diseases
Developing treatments for diseases within the central nervous system, rare diseases, endocrinology, oncology and supportive care.
Events
Upcoming events
-
12May
Interim Report January-March 2026 – Webcast
Financial analysts, investors and media are invited to attend a webcast and presentation of the results at 2:00 pm CET.
Access the webcast using this link: Webcast
To participate in the presentation and ask questions, please register using the link below. After registering, please use the provided phone number and conference ID to dial in. Register to dial in
-
28May
Annual General Meeting 2026
The Annual General Meeting in Camurus will be held on Thursday 28 May 2026 at 5:00 pm CET.
-
03Jun
Handelsbanken Nordic Small & Mid Cap Seminar 2026
Camurus’ Chief Business Development Officer Fredrik Joabsson is presenting at this conference in Stockholm, 3 June. The presentation can be seen by the conference participants. More information will follow closer to the event.
Annual General Meeting
Camurus’ Annual General Meeting 2026 will be held at 5:00 pm CEST on 28 May 2026 at The Loop, Rydbergs torg 4, SE-224 84, Lund, Sweden.
Notification of attendance at the AGM:
https://www.euroclear.com/sweden/generalmeetings/
Documents:
See documents for Annual General Meeting 2026
See more information on Camurus general meetings
Latest financial report
Camurus’ Interim Report January-March 2026
12 May 2026
Annual Report 2025
Pipeline
Diversified pipeline with large potential
Camurus’ innovative product candidates are designed to address important unmet medical needs, with the potential to make significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery.
Sustainability
Sustainable solutions for a healthier world
Ensuring the long-term successful development of our business – for the benefit of patients, healthcare systems, employees and shareholders.
